LondonAbivax shares rose 25% as cancer concerns eased.
The France-based biotech’s maintenance trial showed strong remission rates; cancer cases among participants had triggered a share collapse.
Markets moved before regulators; the safety data still requires review before obefazimod can reach patients.
Sources: STAT